does glp-1 cause cancer Risk of pancreatic associated with receptor agonist therapy GLP-1s tied to lower risk

Thats what makes scientists think these drugs might do far more than manage weight

Unintentional weight loss exceeding expected therapeutic goals, or inability to maintain adequate nutritional intake, requires assessment for excessive medication effect or other underlying conditions

Verdict : Go (for market stability and brand recognition)

persistent, severe abdominal pain) Hypersensitivity to DPP-4 inhibitors in the past Pregnancy/breastfeeding Some DPP-4 inhibitors are contraindicated at certain thresholds of renal impairment (see Table 2 ) Some DPP-4 inhibitors are contraindicated in hepatic impairment (see Table 3 ) Type 1 diabetes Diabetic ketoacidosis Cautions History of pancreatitis Moderate heart failure (saxagliptin only, due to limited experience) Severe heart failure (saxagliptin and vildagliptin, due to limited experience) Some DPP-4 inhibitors are cautioned at certain thresholds of renal impairment, and dose reductions may be required (see Table 2 ) Drug interactions No significant interactions have been reported between DPP-4 inhibitors and any other drugs

For small doses (5-10 units), the liquid volume will be very small, barely visible in the syringe

Trial data can help patients understand general medication trends, but a physician must interpret that information in the context of the individual patients health history, side-effect risk, current medications, and long-term goals